Clay Siegall is the present Chief Executive Officer of Seattle Genetics. Recently, he blogged about Terrelle Pryor, a wide receiver (American Football). His March 7, 2017, post states that football giants like Eagles, Forty-Niners, Titans, and Steelers were portraying interest in the player. This is because Terrelle had impressive scores in his first year as a wide receiver with 77 catches (1,007 yards).
Siegall’s post on the National Public Radio reported that Medical Breakthroughs usually do not prove out. Besides, the study found out that just approximately 50% of the medical findings, which were drafted in the 199 English-language newspapers, held up when they were tested in further studies. This problem is partly brought about by journalists who usually focus on the unexpected and new findings, which medical journals happily promote.
Clay Siegall, PhD., co-founded Seattle Genetics Company in 1998. Today, he serves as the company’s President and CEO. As a prominent scientist on besieged cancer therapies, he constructed Seattle Genetics taking into account rigorous research, drug development practices, and scientific innovation. Moreover, he has led the company to its current position in advancing ADCs for the treatment of cancer.
Under Dr. Siegall’s leadership, Seattle Genetics has engaged in various strategic licenses including AbbVie, Roche, Pfizer and GlaxoSmithKline for its ADC research. These licenses have generated over 350 million US dollars to date. He has also led the company in capital-raising activities, which made over 1.2 billion US dollars through private and public financings.
Before co-founding Seattle Genetics, Siegall worked with the Bristol-Myers Squibb Pharmaceutical Research Institute for six years from 1991. Moreover, he is helping on the Boards of Directors of Alder Biopharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceuticals. Dr. Siegall studied his degree in Bachelor of Science (Zoology) at the University of Maryland. After his first degree, he joined The George Washington University to study for his Ph.D. in Genetics.
In January 2013, Mirna Technologies announced on their blog that Dr. Siegall is the newest member of their Board of Directors. Dr. Siegall is well known in the field of science, because of the significant advancements he and his Seattle Genetics team have made in their research on cancer treatment. As a result, Mirna Technologies said that they looked forward to collaborating with Dr. Siegall.